PDCD1 and hepatocellular carcinoma: Current randomized trials of immune checkpoint inhibitor therapy, such as anti-programmed cell death protein 1 (anti-PD-1) and anti-programmed cell death-ligand protein 1 (anti-PD-L1) monotherapy, do not demonstrate significant improvement in overall survival against HCC [6].